How Elicio Therapeutics $ELTX Is Taking A Different Approach To Treating Cancers
- 4 months ago
Founded in 2011, Elicio Therapeutics Inc. strives to use precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors.
Elicio’s proprietary Amphiphile or “AMP” platform differentiates the company through the development of cancer immunotherapies for patients with limited treatment options and often poor outcomes.
As the foundation for the various vaccine candidates in the biotech company’s pipeline, the AMP platform will help Elicio combat cancer and other diseases.
Elicio’s proprietary Amphiphile or “AMP” platform differentiates the company through the development of cancer immunotherapies for patients with limited treatment options and often poor outcomes.
As the foundation for the various vaccine candidates in the biotech company’s pipeline, the AMP platform will help Elicio combat cancer and other diseases.